In this exclusive interview, Mark Chao (Forty Seven Inc’s Co-Founder & VP of Clinical Development) discusses why the CD47/SIRPα Checkpoint is so exciting and highlights the conversations that need to happen now for this field to accelerate.

Click here to download your copy.